Climb Bio, Inc.

For the period ended Mar 31, 2026. Filed May 7, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 7, 2026

CLYM$11.01+7.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(In thousands, except share and per share amounts)

	March 31,	December 31,
	2026	2025
Assets
Current assets:
Cash and cash equivalents	$8,356	$35,685
Short-term marketable securities	101,208	65,395
Prepaid expenses and other current assets	3,840	4,769
Total current assets	113,404	105,849
Long-term marketable securities	36,741	59,572
Operating lease right-of-use assets	447	505
Property and equipment, net	250	288
Other long-term assets	1,530	1,530
Total assets	$152,372	$167,744
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$860	$2,269
Accrued expenses and other current liabilities	2,948	4,459
Operating lease liabilities	263	256
Total current liabilities	4,071	6,984
Operating lease liabilities, net of current portion	216	285
Total liabilities	4,287	7,269
Commitments and contingencies (Note 6)
Stockholders’ equity:
Common stock, $0.0001 par value; 250,000,000 shares authorized; 47,768,543 and 47,766,338 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively	5	5
Additional paid-in capital	451,372	449,762
Accumulated other comprehensive income	157	435
Accumulated deficit	(303,449)	(289,727)
Total stockholders’ equity	148,085	160,475
Total liabilities and stockholders’ equity	$152,372	$167,744

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.